PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

BACKGROUND. PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded and failed in predicting responders for different cancer types. We sought to describe the PD-L1 expressio...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JCI Insight
Главные авторы: Yarchoan, Mark, Albacker, Lee A., Hopkins, Alexander C., Montesion, Meagan, Murugesan, Karthikeyan, Vithayathil, Teena T., Zaidi, Neeha, Azad, Nilofer S., Laheru, Daniel A., Frampton, Garrett M., Jaffee, Elizabeth M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2019
Предметы:
Clinical Medicine
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482991/
https://ncbi.nlm.nih.gov/pubmed/30895946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.126908
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы